US Price Negotiation Process: Is Case-By-Case Politically Sustainable?

 
• By Michael McCaughan

Republican Congressional letter asking HHS nuts-and-bolts questions about the newly enacted drug price ‘negotiation’ law points to a much more fundamental issue: can a bureaucratic agency make the program work in a manner that appears credible and free of undue political interference?

negotiation seesaw
HHS appears to have the advantage on Medicare drug pricing, but the new ‘negotiation’ process will inevitably involve outside pressure that may shift the balance. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Pricing Debate

More from Market Access